Votrient approved for sarcoma

On April 26, 2012  the FDA announced approval of pazopanib (votrient) for soft tissue sarcoma.

Earlier the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee voted March 20, 2012  to approve a New Drug Application for pazopanib tablets (Votrient, GlaxoSmithKline) in the treatment of patients with advanced soft tissue sarcoma who have received previous chemotherapy.  Although patients with gastrointestinal stromal tumors (GIST) and adipocytic sarcomas were not included in the phase 3 trial upon which the committee approval was based, if the full FDA approves pazopanib for treatment of sarcoma, that may still make it easier for GIST patients to get insurance coverage for this drug.


Post a comment